Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-26
DOI
10.1007/s40261-022-01160-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
- (2022) Rebecca L. Tisdale et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2021) Kirsten L. Johansen et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- POS-335 COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS A TREATMENT FOR CHRONIC KIDNEY DISEASE: A HEALTH-ECONOMIC ANALYSIS OF DAPA-CKD
- (2021) P. MCEWAN et al. Kidney International Reports
- Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China
- (2021) Wen-Qiang Lin et al. Frontiers in Endocrinology
- Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
- (2020) Phil McEwan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
- (2020) Rungroj Krittayaphong et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)
- (2020) Hitoshi Ishii et al. Diabetes Therapy
- Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
- (2020) Michael Willis et al. Diabetes Therapy
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
- (2019) Carol Pollock et al. Lancet Diabetes & Endocrinology
- Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
- (2019) Daniel M. Sugrue et al. PHARMACOECONOMICS
- Health Care Utilization and Burden of Diabetic Ketoacidosis in the U.S. Over the Past Decade: A Nationwide Analysis
- (2018) Dimpi Desai et al. DIABETES CARE
- Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
- (2018) Elaine Nguyen et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients
- (2018) Noman Paracha et al. Health and Quality of Life Outcomes
- Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective
- (2017) Thomas W. Ferguson et al. KIDNEY INTERNATIONAL
- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Impact of Diabetes-Related Complications on Preference-Based Measures of Health-Related Quality of Life in Adults with Type I Diabetes
- (2016) Tessa Peasgood et al. MEDICAL DECISION MAKING
- Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore
- (2016) Fan Yang et al. NEPHROLOGY
- Loss of health related quality of life following low-trauma fractures in the elderly
- (2016) Jean-Eric Tarride et al. BMC Geriatrics
- Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study
- (2016) Tony B. Amos et al. JOURNAL OF MEDICAL ECONOMICS
- Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study
- (2016) Mark D. Jesky et al. PLoS One
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease
- (2015) Reiko Okubo et al. Sleep and Breathing
- The Effect of Hypoglycemia on Health-Related Quality of Life: Canadian Results from a Multinational Time Trade-off Survey
- (2014) Stewart Harris et al. Canadian Journal of Diabetes
- Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years
- (2014) S. Grandy et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
- (2013) David M. Nathan et al. DIABETES CARE
- Assessing the cost-effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model
- (2013) P. Thokala et al. DIABETIC MEDICINE
- Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries
- (2013) Marc Evans et al. Health and Quality of Life Outcomes
- Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
- (2013) Kevin F. Erickson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A health economic analysis of clinical islet transplantation
- (2011) Jessica Beckwith et al. CLINICAL TRANSPLANTATION
- Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: Cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands
- (2010) Cornelis Boersma et al. CLINICAL THERAPEUTICS
- The financial impact of immunosuppressant expenses on new kidney transplant recipients*,†
- (2010) Elisa J. Gordon et al. CLINICAL TRANSPLANTATION
- The cost-effectiveness of increasing kidney transplantation and home-based dialysis
- (2009) KIRSTEN HOWARD et al. NEPHROLOGY
- Microalbuminuria in Type 2 Diabetes and Hypertension: A marker, treatment target, or innocent bystander?
- (2008) S. Basi et al. DIABETES CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now